Biogen Idec (BIIB) Shares Given a "Neutral" Rating by JPMorgan Chase & Co …LocalizedUSAIt includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon…
Neue Daten, die auf dem 5. gemeinsamen Kongress von ECTRIMS und ACTRIMS …Business Wire (Pressemitteilung)Zu den Highlights gehören: DAC HYP ist eine einmal monatlich subkutan verabreichte Daclizumab-Formulierung zur Behandlung von RRMS, die sich in …
Samenvatting: Gegevens gepresenteerd op het vijfde gezamenlijke driejaarlijkse …Business Wire (persbericht)… (fampridine met verlengde afgifte), evenals twee experimentele stoffen in de late fase, het orale geneesmiddel BG-12 (dimethyl fumaraat) en…
Data Presented At The 5th Joint Triennial Congress Of ECTRIMS And ACTRIMS …TheStreet.com (press release)… marketed products, TYSABRI ® (natalizumab), AVONEX ® (interferon beta-1a) and FAMPYRA ® (prolonged-release fampridine), as well as two late…
Earnings Preview: Akamai, Advanced Micro Devices, Gilead Sciences, Biogen, CelgeneSeeking AlphaTysabri sales over $280 million would be a positive indicator, but the key question is data or FDA approvals for late-pipeline drugs like BG-12 or Daclizumab…
Abbott feiert 125 Jahre Pharmastandort LudwigshafenÄrzte ZeitungAuch klinische Projekte werden hier koordiniert. Aktuelle Beispiele sind laut Richter Phase-III Studien mit dem Krebsmittel Linifanib, dem MS-Antikörper Daclizumab sowie mit Bardoxolon g…
InPharmMerck KGaA signs MS and cancer research dealInPharmIn August Biogen and Abbott's MS drug daclizumab, a new injectable, performed well in a Phase IIb study, although two deaths marred the overall results. But Novartis' oral drug Gilenya (…
Biogen Idec (BIIB) Upgraded by William Blair to "Outperform"LocalizedUSAIt includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1a. Shares of B…
The Daily DealAbbott's emerging entranceThe Daily DealFacet had partnered with Biogen Idec Inc. on a multiple sclerosis drug, known as daclizumab, a monoclonal antibody being considered for uses ranging from the prevention of organ rejection in tra…
Abbott Laboratories Offering Investors Expanded Late-Stage Drug PipelineSeeking AlphaWith the purchase came multiple-sclerosis drug daclizumab and late-stage multiple-myeloma treatment elotuzumab, which have both given encouraging Phase II data so far….